Comparison of overall efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis.

Abstract

Subcutaneous (SC) methotrexate (MTX) is considered to be associated with a higher and predictable linear bioavailability as compared to oral MTX. Although various studies have reported SC MTX to be safe and effective in psoriasis, prospective head-to-head comparative trials on oral versus SC MTX are limited. To compare the efficacy and safety of SC versus oral MTX in severe psoriasis. It was a prospective, single-blinded, randomized controlled trial, in 100 eligible, adult patients of severe psoriasis randomized into two groups. Group-A (n= 50) patients were started on oral MTX at a full dose of 0.3mg/kg/week (maximum 25 mg/week) given for 12 weeks or till achieving PASI90 [90% reduction in Psoriasis Area Severity Index (PASI) from baseline], whichever was earlier and group-B (n= 50) patients received SC MTX in the same dose and duration. MTX was then tapered gradually at 5mg every 2 weeks and stopped. All patients were followed-up for 24 weeks post-treatment with monthly assessment of PASI and Dermatology Life Quality Index (DLQI) scores. Baseline demographic profiles of patients in both the groups were comparable. The mean ±SD baseline PASI scores were group-A: 15.1± 3.2 versus group-B:15.7± 3.3 (p= 0.35). The number of patients that achieved PASI90 at or before 12 weeks of treatment was numerically higher in group-B (39/50, 78%) versus group-A (31/50, 62%; p= 0.08) and the time to achieve PASI90 was significantly lesser (p< 0.001).Also, the percentage(%) decline in DLQI was significantly higher in group-B(p= 0.003). The overall side-effect profile was comparable between groups (p= 0.31), but the frequency of gastrointestinal side-effects was significantly less in group-B (p= 0.04). Among those patients who achieved a PASI90 response by week12, relapse rates were comparable during the subsequent 24-week follow-up period [group-A: 12/31 (39%), group-B: 11/39 (28%), and p-value=0.33]. SC MTX results in a significantly faster achievement of PASI90 and greater reduction in DLQI as compared to oral MTX in patients who are candidates for systemic therapy with a comparable safety profile. CTRI/2018/01/011373, date of registration: 15 January, 2018; trial registered prospectively.